Cargando…

Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer

The programmed death-1 (PD-1) signaling pathway serves a critical role in immune regulation and tolerance by suppressing the activation and proliferation of T cells. The aim of the present study was to investigate the effect of PD-1 and programmed death-ligand 1 (PD-L1) on the development of cervica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ying, Zhu, Weipei, Zhang, Xueguang, Qu, Qiuxia, Zhang, Liyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754902/ https://www.ncbi.nlm.nih.gov/pubmed/29344157 http://dx.doi.org/10.3892/ol.2017.7105

Ejemplares similares

Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients
por: Zhang, Yan, et al.
Publicado: (2011)

Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas
por: Yang, Min-Wei, et al.
Publicado: (2019)

Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
por: Chen, Kaiyan, et al.
Publicado: (2016)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Lymphocyte activation gene-3 is associated with programmed death-ligand 1 and programmed cell death protein 1 in small cell lung cancer
por: Sun, Hui, et al.
Publicado: (2021)

Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
por: Luo, Fan, et al.
Publicado: (2021)

Clinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8(+) T Lymphocytes in Ovarian Carcinosarcoma
por: Zhu, Jun, et al.
Publicado: (2017)

Correction to: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
por: Luo, Fan, et al.
Publicado: (2022)

Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
por: Reddy, Opal L., et al.
Publicado: (2017)

The significance of programed cell death‐ligand 1 expression in vestibular schwannoma
por: Lee, Se A, et al.
Publicado: (2023)

Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitis
por: Pan, Tingting, et al.
Publicado: (2017)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
por: Ganbaatar, Otgontuya, et al.
Publicado: (2021)

Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
por: Mikami, Shuji, et al.
Publicado: (2019)

Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells
por: Chen, Zhifang, et al.
Publicado: (2016)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
por: Yim, Nam-Hui, et al.
Publicado: (2020)

Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease
por: Goto, Hiroyuki, et al.
Publicado: (2021)

Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8(+) lymphocytes in primary sarcomas is subtype dependent
por: van Erp, Anke E.M., et al.
Publicado: (2017)

Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
por: Kim, Ji-Hyun, et al.
Publicado: (2019)

Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus
por: Liu, Ming-Fei, et al.
Publicado: (2009)

The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma
por: Wu, Shafei, et al.
Publicado: (2017)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression
por: Asai, Akira, et al.
Publicado: (2020)

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
por: Liu, Xiaojun, et al.
Publicado: (2016)

Cbl-b Deficiency Mediates Resistance to Programmed Death-Ligand 1/Programmed Death-1 Regulation
por: Fujiwara, Mai, et al.
Publicado: (2017)

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
por: Liu, Qiang, et al.
Publicado: (2017)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

Programmed death ligand 1 and tumor-infiltrating CD8(+) T lymphocytes are associated with the clinical features in meningioma
por: Zhang, Yaochuan, et al.
Publicado: (2022)

The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis
por: Zhang, Jingyi, et al.
Publicado: (2021)

Expression of peripheral monocytic programmed death ligand-1 in severe sepsis combined with HBV-related cirrhosis. A pilot observational study
por: Lu, Yi, et al.
Publicado: (2021)

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
por: Shen, Xiangfeng, et al.
Publicado: (2019)

Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T‐cell lymphomas
por: Zhang, Xuhan, et al.
Publicado: (2019)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients
por: Yun, Sumi, et al.
Publicado: (2019)

Programmed death ligand‐1 expression in gastrointestinal cancer: Clinical significance and future challenges
por: Yamashita, Kohei, et al.
Publicado: (2020)

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer
por: Zhang, Jian, et al.
Publicado: (2019)

Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy
por: Wang, Yiming, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fd6utg7lrpiq6nefm4tl82q3ou